CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

Conditions: Idiopathic Inflammatory Myopathies; Diffuse Cutaneous Systemic Sclerosis; SLE Nephritis; ANCA Associated Vasculitis Interventions: Drug: KYV-101; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: David Porter; Kyverna Therapeutics Not yet recruiting

https://clinicaltrials.gov/study/NCT06152172

Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials